Screener
Sana Biotechnology SANA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease right-of-use assets and liabilities | (1,496) | 891 |
| Accounts payable | 454 | (4,224) |
| Accrued expenses and other liabilities | (7,094) | (8,893) |
| Net cash used in operating activities | (37,379) | (48,657) |
| INVESTING ACTIVITIES: | ||
| Purchases of marketable securities | (5,588) | (1,682) |
| Proceeds from maturities of marketable securities | 55,065 | 18,168 |
| Purchases of property and equipment | (288) | (136) |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's operating cash flow?
- Sana Biotechnology (SANA) reported operating cash flow of -$37.38M in Q1 2026.
- How has Sana Biotechnology's operating cash flow changed year-over-year?
- Sana Biotechnology's operating cash flow increased by 23.2% year-over-year, from -$48.66M to -$37.38M.
- What is the long-term trend for Sana Biotechnology's operating cash flow?
- Over 4 years (2021 to 2025), Sana Biotechnology's operating cash flow has grown at a -13.0% compound annual growth rate (CAGR), from -$251.05M to -$143.83M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Sana Biotechnology's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude